The relationship between SGLT2 inhibitors and heart failure
Studies done by the Journal of the American Heart Association show that people with diabetes are susceptible to heart failure. These studies also show that SGLT2 inhibitors help reduce the risk of hospitalization caused by heart failure by 23 percent. No matter the history of hardened arteries [4], cardiovascular conditions, or heart failures.
People without diabetes can also take SGLT2 inhibitors for various purposes.
According to studies, Farxiga (dapagliflozin) prevents the exacerbation of heart failure or death due to heart failure and reduced ejection fraction in people who have type 2 diabetes and people who don’t. Farxiga is approved by the FDA to treat this form of heart failure [5].